<?xml version="1.0" encoding="UTF-8"?>
<p>Tenofovir disoproxil fumarate is a nucleoside analogue originally licensed for treatment for HIV infection. The dose for tenofovir in adults is higher than that of adefovir (300 mg/day) and has a greater antiviral activity than adefovir in clinical trials (undetectable HBV DNA in 76 % of patients vs. 13 % of adefovir-receiving subjects after 48 weeks of treatment) [
 <xref ref-type="bibr" rid="CR116">116</xref>]. No genotypic resistance to tenofovir has yet been confirmed. A phase III trial is ongoing on 12â€“17-year-old patients [
 <xref ref-type="bibr" rid="CR117">117</xref>] (Table 
 <xref rid="Tab2" ref-type="table">15.2</xref>). 
</p>
